1Ganeval D,Rabian C,Guerin V,et al.Treatment of multiple myeloma with renal involment.Adv Nephrol Necker Hosp,1992,21:347-370.
2Sanchorawala V,Wright DG,Dember LM,et al.An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.Bone Marrow Transplant,2001,28(7):637-642.
3Alexanian R,Barlogie B,Dixon D.Renal failure in multiple myeloma.Pathogenisis and prognostic implication.Arch Intern Med,1990,150(8):1693-1695.
4Shimamoto Y, Anami Y, Yamaguchi M. A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients[ J]. Eur J Haematol, 1991,47:262 - 267.
5Kim MK, Suh C, Lee DH, et al. Immunoglobulin D multiple myelo- ma : response to therapy, survival, and prognostic factors in 75 patients[J]. Ann Oncol,2011,22(2) :411 -416.
6Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma : presentingfeatures, response to therapy, and survival in a series of 53 cases[ J ]. J Clin Oncol, 1994,12:2398 - 2404.
7陈慰峰.医学免疫学[M].3版.北京:人民卫生出版社.2002.
8Prakash J, Mandal AK, Vohra R,et al. Renal disease is a prodrome of multiple myeloma: an analysis of 50 patients from eastern India[J].Ren Fail, 2009, 31 (4): 267-271.
9Hernandez-Reyes J, Galo-Hooker E, Ruiz-Delgado GJ , et al.Systemic immunoglobulin light-chain amyloidosis (AL) in Mexico: a single institution, 30-year experience[J]. Rev Invest Clin, 2012, 64(6 Pt 2): 604-608.
10Gertz MA. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment[J]. Am J Hematol, 2013, 88(5): 416-425.
